Wire
Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15
Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15
$ABT
$ABT
25 stories mentioning ABT
Every FINWIRES story that references ABT, newest first.
Wire
Abbott Gets CE Mark for Glucose-Ketone Sensing Technology for Diabetes
Abbott (ABT) said Wednesday it has secured the CE Mark for its dual glucose-ketone sensing technology for people with diabetes.The systems, branded as Libre Duo and Libre Duo 10 Day, are designed to continuously measure glucose and ketone levels every minute, the company said.Abbott said it plans to start launching Libre Duo systems in some European countries later this year.Price: $86.44, Change: $-0.23, Percent Change: -0.27%
$ABT
Wire
Abbott Laboratories Says Ultreon 3.0 Coronary Imaging Software Receives FDA Clearance, CE Mark
Abbott Laboratories (ABT) said Tuesday that it received US Food and Drug Administration clearance and the European Union's CE Mark for its Ultreon 3.0 artificial intelligence-powered coronary imaging software.The software uses optical coherence tomography to support doctors performing minimally invasive procedures to open blocked heart arteries, known as percutaneous coronary intervention, the company said.Abbott said the software helps doctors choose the best stent location and size to improve blood flow, thereby enabling faster, more precise procedures.Shares of the company were up 1.1% in Tuesday's trading.Price: $93.58, Change: $+0.78, Percent Change: +0.84%
$ABT
Research
Daiwa Downgrades Abbott Laboratories to Neutral From Outperform, Adjusts PT to $92 From $113
Abbott Laboratories (ABT) has an average rating of overweight and mean price target of $119.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ABT
Wire
Argus Cuts Abbott Laboratories' Price Target to $125 From $140
Abbott Laboratories (ABT) has an average rating of overweight and mean price target of $120.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $96.06, Change: $-0.75, Percent Change: -0.77%
$ABT
Wire
UBS Adjusts Abbott Laboratories Price Target to $135 From $158, Maintains Buy Rating
Abbott Laboratories (ABT) has an average rating of overweight and mean price target of $120.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $96.95, Change: $+0.13, Percent Change: +0.14%
$ABT
Sectors
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) gained 1.6%.In corporate news, Abbott Laboratories' (ABT) end-markets remain healthy despite a lower 2026 organic revenue guidance amid fiscal Q1 challenges and mixed performance, RBC Capital Markets said in a note. Abbott shares rose 1.7%.Merck (MRK) shares added 2.8% after it said Friday that the European Commission has approved Enflonsia to prevent respiratory tract disease in newborns and infants.Kura Oncology (KURA) shares jumped past 9% after it said Friday that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.Psyence Biomedical (PBM) shares surged 30% after it acknowledged recent reports saying that the US administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder, addiction, and other serious neurological and mental health conditions. Through its investment in PsyLabs, Psyence has established a position in the manufacturing of ibogaine and ibogaine derivatives, it said.
$ABT$KURA$MRK$PBM
Sectors
Sector Update: Health Care
Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) advanced 1.4%.In corporate news, Abbott Laboratories' (ABT) end-markets remain healthy despite a lower 2026 organic revenue guidance amid fiscal Q1 challenges and mixed performance, RBC Capital Markets said in a note. Abbott shares rose 1.5%.
$ABT
Wire
Abbott Laboratories' End-Markets Remain Healthy Despite Mixed Q1 Performance, RBC Says
Abbott Laboratories' (ABT) end-markets remain healthy despite a lower 2026 organic revenue guidance amid fiscal Q1 challenges and mixed performance, RBC Capital Markets said in a Thursday research note.The company faced Q1 headwinds, including a weaker respiratory season, underperformance in the continuous glucose monitoring segment, challenging US structural heart business trends, and roadblocks in the nutrition sector, analysts wrote.The brokerage said it expects 2026 EPS of $5.48 on revenue of $50.54 billion.The company has visibility to accelerate growth in H2, driven by emerging signs of nutrition business recovery, electrophysiology unit growth, improvements in the core lab diagnostics unit, robust performance in established pharmaceuticals, and the integration of Exact Sciences in the cancer diagnostics business, according to the note.The brokerage reiterated its outperform rating on the stock and adjusted its price target to $130 from $135.Price: $96.67, Change: $+1.20, Percent Change: +1.26%
$ABT
US Markets
Nasdaq, S&P 500 Score Back-to-Back Record Highs
The Nasdaq Composite and the S&P 500 reached new peaks Thursday amid growing hopes for a resolution to the Middle East conflict.The Nasdaq rose 0.4% to 24,102.7, while the S&P 500 climbed 0.3% to 7,041.3, both notching record closing highs for a second consecutive day. The Nasdaq extended its winning streak to 12 days in a row.The Dow Jones Industrial Average added 0.2% to 48,578.7.Most sectors ended in the green, led by energy, while health care saw the biggest drop.US President Donald Trump said Thursday that Lebanon and Israel agreed to a 10-day ceasefire.Trump said in a social media post that he will invite Israeli Prime Minister Benjamin Netanyahu and Lebanese President Joseph Aoun to the White House for "meaningful talks.""Both sides want to see peace, and I believe that will happen, quickly," he wrote.The ceasefire seeks to pause hostilities between Israel and Iran-backed Hezbollah in Lebanon, a key sticking point in peace negotiations between the US and Tehran.West Texas Intermediate crude oil was up 2.4% at $93.50 a barrel in Thursday late-afternoon trade, while Brent advanced 3.4% to $98.19."Oil is up over doubts that the Strait of Hormuz disruption will ease soon," D.A. Davidson said in a report.US Treasury yields were higher, with the 10-year rate up 2.6 basis points at 4.31% and the two-year rate rising 1.6 basis points to 3.79%.In company news, IBM (IBM) shares rose 2.5%, the third-top gainer on the Dow. The tech giant will likely exceed Wall Street's estimates for the first quarter and raise its revenue guide amid momentum in the software segment and an earlier completion of the Confluent acquisition, Oppenheimer said in a note. IBM is scheduled to announce its quarterly results next week.Charles Schwab (SCHW) shares dropped 7.6%, the steepest decline on the S&P 500. The financial services provider's first-quarter results rose year over year amid a surge in client assets, though revenue fell short of the Street's estimates.Abbott Laboratories (ABT) followed Charles Schwab on the S&P 500, down 6%. The healthcare company lowered its full-year earnings outlook to reflect the acquisition of cancer diagnostics firm Exact Sciences.PepsiCo (PEP) reported higher-than-expected fiscal first-quarter results amid affordability initiatives, while the beverage and snacks company reiterated its full-year outlook. Its shares rose 2.3%.In economic news, US industrial production unexpectedly decreased in March, Federal Reserve data showed.It's too soon to blame the Middle East conflict for the drop, which was driven by "sharply falling" output in the mining and utilities sectors, Oxford Economics said in a note.Gold was last down 0.2% at $4,813.70 per troy ounce, while silver fell 1.2% to $78.68 per ounce.
Dow JonesNasdaq CompositeS&P 500$ABT$IBM$PEP$SCHW
Sectors
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 1.3%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell past 5%.Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a note. Gilead shares were down 0.8%.QuidelOrtho (QDEL) shares tumbled 28%. The company said late Wednesday it expects preliminary unaudited revenue of $615 million to $620 million for Q1. Analysts polled by FactSet expect $677.8 million.Hims & Hers Health (HIMS) shares jumped past 12% after a senior US health official signaled plans to ease restrictions on certain peptides.
$ABT$GILD$HIMS$QDEL
US Markets
Equity Markets Rise Intraday as Trump Announces Israel-Lebanon Ceasefire
US benchmark equity indexes were higher intraday as President Donald Trump said Lebanon and Israel agreed to a 10-day ceasefire, adding to optimism around prospects for peace in the Middle East.The Nasdaq Composite was up 0.4% at 24,100.4 after midday Thursday, while the S&P 500 rose 0.2% to 7,037.9. Both benchmarks closed at record highs in the previous session. The Dow Jones Industrial Average was 0.1% higher at 48,528.2 intraday Thursday.Among sectors, energy paced the gainers, while health care saw the biggest drop.Trump said Thursday the ceasefire between Lebanon and Israel would begin at 5 pm ET."I will be inviting the Prime Minister of Israel, Bibi Netanyahu, and the President of Lebanon, Joseph Aoun, to the White House for the first meaningful talks between Israel and Lebanon since 1983," Trump said in a social media post. "Both sides want to see peace, and I believe that will happen, quickly."Lebanese Prime Minister Nawaf Salam welcomed Trump's announcement, which seeks to pause hostilities between Israel and Iran-backed Hezbollah in Lebanon, CNN reported. Hezbollah will abide by the ceasefire if Israeli attacks stop, the news outlet reported, citing a leading Hezbollah legislator, Ibrahim Moussawi.West Texas Intermediate crude oil was up 4.4% at $95.29 a barrel intraday, while Brent jumped 5.1% to $99.76."Oil is up over doubts that the Strait of Hormuz disruption will ease soon," D.A. Davidson said in a report.It will take about six months for the US and Iran to reach a peace deal, and the two sides should extend their ceasefire to cover that period, Bloomberg News reported Thursday, citing Gulf Arab and European officials familiar with the matter.US Treasury yields were higher intraday, with the 10-year rate up three basis points at 4.31% and the two-year rate rising one basis point to 3.77%.In company news, IBM (IBM) shares rose 2.4%, the second-top gainer on the Dow. The tech giant will likely exceed Wall Street's estimates for the first quarter and raise its revenue guide amid momentum in the software segment and an earlier completion of the Confluent acquisition, Oppenheimer said in a note.Abbott Laboratories (ABT) shares dropped 6.8%, the steepest decline on the S&P 500, after the healthcare company lowered its full-year earnings outlook to reflect the acquisition of cancer diagnostics firm Exact Sciences.Charles Schwab (SCHW) followed Abbott on the S&P 500, down 6%. The financial services provider's first-quarter results rose year over year amid a surge in client assets, though revenue fell short of the Street's estimates.In economic news, US industrial production unexpectedly decreased in March, Federal Reserve data showed.It's too soon to blame the Middle East conflict for the drop, which driven by "sharply falling" output in the mining and utilities sectors, Oxford Economics said in a note.Gold was down 0.3% at $4,807.10 per troy ounce, while silver fell 1.6% to $78.38 per ounce.
Dow JonesNasdaq CompositeS&P 500$ABT$IBM$SCHW
Wire
Evercore ISI Adjusts Abbott Laboratories Price Target to $120 From $134, Maintains Outperform Rating
Abbott Laboratories (ABT) has an average rating of overweight and mean price target of $132.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $95.28, Change: $-6.29, Percent Change: -6.19%
$ABT
Sectors
Sector Update: Health Care Stocks Slide in Afternoon Trading
Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1%.The iShares Biotechnology ETF (IBB) dropped 1.2%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell past 6%.QuidelOrtho (QDEL) shares tumbled 31%. The company said late Wednesday it expects preliminary unaudited revenue of $615 million to $620 million for Q1. Analysts polled by FactSet expect $677.8 million.Hims & Hers Health (HIMS) shares rose past 7% after a senior US health official signaled plans to ease restrictions on certain peptides.Organon (OGN) is a potential acquisition target by India's Sun Pharmaceutical Industries, Germany's Grunenthal, and private equity firms, Bloomberg reported. Organon shares added 0.7%.
$ABT$HIMS$OGN$QDEL
Sectors
Sector Update: Health Care
Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1%.The iShares Biotechnology ETF (IBB) dropped 1.2%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell 7%.
$ABT
Research
Research Alert: CFRA Keeps Buy Rating On Shares Of Abbott Laboratories
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $125, 20.0x our 2027 EPS estimate. This is a discount to ABT's historical forward average despite strategic portfolio enhancement via the Exact Sciences (EXAS) deal and the strong innovation pipeline, in our view. We adjust our 2026 EPS view to $5.56 from $5.76 to include the dilution related to EXAS acquisition, and keep our 2027 EPS view at $6.26. ABT delivered significant pipeline milestones in Q1, highlighted by the earlier-than-planned approval and launch of two PFA catheters (Volt in the U.S. and Duo in Europe), completion of patient enrollment in the Catalyst left atrial appendage device trial, and positive trial results demonstrating Libre's benefits for Type 2 diabetes patients on basal insulin therapy. We also remain bullish on the integration of EXAS, which closed slightly earlier than anticipated in late March. The deal positions ABT as a leader in the ~$60B U.S. cancer screening & precision-oncology diagnostics market, which is one of health care's fastest-growing segments.
$ABT
Wire
Top Midday Stories: TSMC Earnings, Guidance Top Estimates But Shares Fall; PepsiCo Shares Rise Following Q1 Earnings Report
All three major US stock indexes were up in late-morning trading Thursday, as investors take in updates on the war in Iran as well as the latest large-company earnings reports.In company news, Taiwan Semiconductor Manufacturing (TSM), or TSMC, reported Q1 earnings Thursday of 22.08 New Taiwan dollars ($0.70) per diluted share, up from NT$13.94 a year earlier and above the FactSet consensus analyst estimate of NT$20.92. First-quarter net revenue was NT$1.134 trillion, up from NT$839.25 billion a year ago and above the FactSet consensus of NT$1.121 trillion. For Q2, the chipmaker said it expects net revenue of $39 billion to $40.2 billion, above the FactSet consensus of $38.09 billion. TSMC shares were down 1.9% around midday.PepsiCo (PEP) reported fiscal Q1 core earnings Thursday of $1.61 per diluted share, up from $1.48 a year earlier and above the FactSet consensus of $1.54. Fiscal Q1 net revenue was $19.44 billion, up from $17.92 billion a year ago and above the FactSet consensus of $18.95 billion. For fiscal 2026, PepsiCo said it continues to expect core constant currency EPS growth of 4% to 6% and organic revenue growth of between 2% and 4%. PepsiCo shares were up 2.1%.Abbott Laboratories (ABT) reported Q1 adjusted earnings Thursday of $1.15 per diluted share, up from $1.09 a year earlier and above the FactSet consensus of $1.14. First-quarter net sales were $11.16 billion, up from $10.36 billion a year ago and above the FactSet consensus of $11.00 billion. For Q2, Abbott said it expected adjusted diluted EPS of $1.25 to $1.31, below the FactSet consensus of $1.36. For full-year 2026, the company said it expects adjusted EPS of $5.38 to $5.58, down from its prior guidance of $5.55 to $5.80 and below the FactSet consensus of $5.60. Full-year 2026 comparable sales are expected to grow 6.5% to 7.5%, the company said. Abbott shares were down 4.4%.Charles Schwab (SCHW) reported Q1 adjusted earnings Thursday of $1.43 per diluted share, up from $1.04 a year earlier and above the FactSet consensus of $1.40. First-quarter net revenue was $6.48 billion, up from $5.60 billion a year ago but below the FactSet consensus of $6.50 billion. The company also said Thursday it will launch a spot cryptocurrency trading service for retail customers in the coming weeks. For a fee of 75 basis points per transaction, the platform will provide direct trading of bitcoin and ethereum alongside traditional investments, the company said. Shares of Schwab were down 4.8%.Stellantis (STLA) and Microsoft (MSFT) said Thursday they have signed a five-year strategic collaboration deal to co-develop advanced artificial intelligence, cybersecurity and engineering capabilities for the automaker's vehicles. Separately, Stellantis is planning a 100-million-euro ($117.9 million) investment to update its Poissy assembly plant near Paris, Bloomberg reported Thursday. The company will continue making vehicles at the facility through at least the end of 2028, the report said. Stellantis shares were down 0.8%, while Microsoft shares were up 1.6%.Oracle (ORCL) said Thursday it plans to expand its multicloud networking capabilities to provide high-performance connectivity between Oracle Cloud Infrastructure and Amazon's (AMZN) Amazon Web Services. Oracle shares were up 4.1%, while Amazon shares were down 0.3%.Sales of Tesla's (TSLA) Cybertruck were boosted by purchases from Elon Musk's other companies, Bloomberg reported Thursday, citing S&P Global Mobility registration data. Tesla shares were down 1.1%.Price: $368.08, Change: $-7.02, Percent Change: -1.87%
$ABT$AMZN$MSFT$ORCL$PEP$SCHW$STLA$TSLA$TSM
US Markets
Abbott Cuts 2026 Earnings Outlook Following First-Quarter Beat
Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported first-quarter results above market estimates.The company now anticipates adjusted earnings of $5.38 to $5.58 per share for 2026, including a $0.20 dilution related to the Exact Sciences purchase. The company previously expected adjusted EPS to come in between $5.55 and $5.80 for the year, while the current consensus on FactSet is for $5.60.Abbott acquired Exact Sciences in March."The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year," Abbott Chief Executive Robert Ford said in a statement.Comparable sales, which includes the prior and current year sales of Exact Sciences, are pegged to grow by 6.5% to 7.5% for 2026, according to the company.Abbott's shares fell 4.1% in Thursday trade, taking its year-to-date loss to 22%.For the three-month period ended March, the firm's adjusted EPS rose to $1.15 from $1.09 the year before, surpassing the Street's view for $1.14. Sales improved 7.8% to $11.16 billion, topping the average analyst estimate of nearly $11 billion. Comparable sales were up 3.7%.Diagnostics sales rose 6.1% year over year to $2.18 billion, while the nutrition segment dropped 6% to $2.02 billion amid lower sales volume and pricing actions in the previous quarter, according to the company. Revenue in the established pharmaceuticals division climbed 13% to $1.43 billion.Sales in the global medical devices business jumped 13% to $5.54 billion, led by gains of 17% each in rhythm management and electrophysiology, Abbott said. Within the segment, the company recorded double-digit growth in heart failure and diabetes care.For the second quarter, Abbott forecasts adjusted EPS of $1.25 to $1.31, while the Street is looking for $1.36.Price: $97.09, Change: $-4.43, Percent Change: -4.36%
$ABT
Wire
Update: Abbott Laboratories Q1 Adjusted Earnings, Net Sales Rise; 2026 Adjusted EPS Guidance Lowered; Shares Fall
(Updates with latest stock price movement in the headline and first paragraph, and previous adjusted EPS guidance in the seventh paragraph.)Abbott Laboratories (ABT) shares were down about 4% in Thursday trading after the company reported Q1 results and lowered 2026 guidance.The company reported Q1 adjusted earnings earlier Thursday of $1.15 per diluted share, up from $1.09 a year earlier.Analysts polled by FactSet expected $1.14.Net sales for the quarter ended March 31 was $11.16 billion, up from $10.36 billion a year earlier.Analysts polled by FactSet expected $11.00 billion.For Q2, Abbott projects adjusted diluted earnings of $1.25 to $1.31 per share. Analysts expect $1.36.The company said it now expects full-year 2026 adjusted earnings of $5.38 to $5.58 per diluted share, compared with its prior guidance of $5.55 to $5.80. Analysts expect $5.60.The company expects full-year 2026 comparable sales growth of 6.5% to 7.5%.Price: $97.13, Change: $-4.44, Percent Change: -4.37%
$ABT
Wire
Correction: --GUIDANCE: (ABT) Abbott Laboratories Expects 2026 Adjusted EPS Range $5.38 to $5.58, vs. FactSet Est of $5.60
Correction: --GUIDANCE: (ABT) Abbott Laboratories Expects 2026 Adjusted EPS Range $5.38 to $5.58, vs. FactSet Est of $5.60
$ABT
Showing 1-20 of 25